Dr. Agarwal on HRQoL and PROs with apalutamide in mCSPC

Neeraj Agarwal, MD, a professor of Medicine at the Huntsman Cancer Institute, University of Utah, discusses health-related quality of life (HRQoL) and patient-reported outcomes from the phase 3 TITAN trial of apalutamide (Erleada) in patients with metastatic castration-sensitive prostate cancer (mCSPC).

The TITAN trial (NCT02489318) randomized 1052 patients with mCSPC in a 1:1 ratio to receive apalutamide plus androgen-deprivation therapy (ADT) or placebo plus ADT. The results showed that adding apalutamide to ADT reduced the risk of death by 35% versus ADT alone.

Based on the efficacy and safety data from the primary TITAN analysis, the FDA approved apalutamide for the treatment of patients with mCSPC.